Browsing Tag
QTORIN
2 posts
Palvella Therapeutics targets first approved microcystic lymphatic malformation therapy with QTORIN filing
Palvella Therapeutics completes its QTORIN FDA filing and prepares for a potential 2027 launch in microcystic lymphatic malformations.
Palvella Therapeutics (NASDAQ: PVLA) rebounds 15% as investors reassess FDA path
Palvella Therapeutics is recovering from a sharp selloff as investors separate its advancing QTORIN rolling application from uncertainty surrounding a second indication.